                                 CODE OF VIRGINIA

SCHEDULE III (§ 54.1-3450)

The controlled substances listed in this section are included in Schedule III:

1. Unless specifically exempted or listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system:
			Any substance which contains any quantity of a derivative of barbituric acid,
or any salt of a derivative of barbituric acid, except those substances which
are specifically listed in other schedules;			Any compound, mixture or
preparation containing amobarbital, secobarbital, or pentobarbital or any salt
of amobarbital, secobarbital, or pentobarbital and one or more other active
medicinal ingredients which are not listed in Schedules II through V;			Any
suppository dosage form containing amobarbital, secobarbital, or pentobarbital
or any salt of amobarbital, secobarbital, or pentobarbital and approved by the
Food and Drug Administration for marketing only as a
suppository;			Chlorhexadol;			Any drug product containing gamma hydroxybutyric
acid, including its salts, isomers, and salts of isomers, for which an
application is approved under section 505 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. &#xA7; 355);			Embutramide;			Ketamine, its salts,
isomers, and salts of isomers (some other names: [+-]
-2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);			Lysergic acid;			Lysergic
acid amide;			Methyprylon;			Perampanel
[2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benxonitrile],
including its salts, isomers, and salts of
isomers;			Sulfondiethylmethane;			Sulfonethylmethane;			Sulfonmethane;
and			Tiletamine-zolazepam combination product or any salt thereof.

2. Nalorphine.

3. Unless specifically excepted or unless listed in another schedule:
			a. Any material, compound, mixture, or preparation containing any of the
following narcotic drugs or their salts thereof:			Buprenorphine.			b. Any
material, compound, mixture, or preparation containing limited quantities of any
of the following narcotic drugs, or any salts thereof:			Not more than 1.8 grams
of codeine, or any of its salts, per 100 milliliters or not more than 90
milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
alkaloid of opium;			Not more than 1.8 grams of codeine, or any of its salts,
per 100 milliliters or not more than 90 milligrams per dosage unit, with one or
more active, nonnarcotic ingredients in recognized therapeutic amounts;			Not
more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters
or not more than 90 milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts;			Not more than 300
milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not
more than 15 milligrams per dosage unit, with one or more ingredients in
recognized therapeutic amounts;			Not more than 500 milligrams of opium per 100
milliliters or per 100 grams, or not more than 25 milligrams per dosage unit,
with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts;			Not more than 50 milligrams of morphine, or any of its salts, per 100
milliliters or per 100 grams with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts.

4. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including its salts, isomers (whether optical, position, or geometric), and
salts of such isomers whenever the existence of such salts, isomers, and salts
of isomers is possible within the specific chemical designation:
			Benzphetamine;			Chlorphentermine;			Clortermine;			Phendimetrazine.

5. The Board may except by regulation any compound, mixture, or preparation
containing any stimulation or depressant substance listed in subsection A from
the application of all or any part of this chapter if the compound, mixture, or
preparation contains one or more active medicinal ingredients not having a
stimulant or depressant effect on the central nervous system, and if the
admixtures are included therein in combinations, quantity, proportion, or
concentration that vitiate the potential for abuse of the substances which have
a stimulant or depressant effect on the central nervous system.

6. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation containing any quantity of the
following substances, including its salts, isomers, and salts of isomers
whenever the existence of such salts of isomers is possible within the specific
chemical designation:
			Anabolic steroids, including, but not limited
to:			3beta,17-dihydroxy-5a-androstane;			3alpha,17beta-dihydroxy-5a-androstane;
			5alpha-androstan-3,17-dione;			1-androstenediol
(3beta,17beta-dihydroxy-5alpha-androst-1-ene);			1-androstenediol
(3alpha,17beta-dihydroxy-5alpha-androst-1-ene);			4-androstenediol
(3beta,17beta-dihydroxy-androst-4-ene);			5-androstenediol
(3beta,17beta-dihydroxy-androst-5-ene);			1-androstenedione
([5alpha]-androst-1-en-3,17-dione);			4-androstenedione
(androst-4-en-3,17-dione);			5-androstenedione
(androst-5-en-3,17-dione);			Bolasterone
(7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);			Boldenone
(Dehydrotestosterone)(17beta-hydroxyandrost-1,4,-diene-3-one);			Boldione
(androsta-1, 4-diene-3, 17-dione);			Calusterone
(7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);			Clostebol
(4-Chlorotestosterone)(Chlorotestosterone)(4-chloro-17beta-hydroxyandrost-4-en-3
-one);			Dehydrochloromethyltestosterone
(4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);			Delta1-dihydr
otestosterone
(1-testosterone)(17beta-hydroxy-5alpha-androst-1-en-3-one);			Desoxymethyltestos
terone (madol)(17alpha-methyl-5alpha-androst-2-en-17beta-ol);			Dromostanolone
(Drostanolone)(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);			Ethylestr
enol (17alpha-ethyl-17beta-hydroxyestr-4-ene);			Fluoxymesterone
(9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);			Formyldie
nolone
(Formebolone)(2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-di
en-3-one);			Furazabol
(17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);			13-beta-ethyl-17alph
a-hydroxygon-4-en-3-one;			4-hydroxytestosterone
(4,17beta-dihydroxy-androst-4-en-3-one);			4-hydroxy-19-nortestosterone
(4,17beta-dihydroxy-estr-4-en-3-one);			Mestanolone
(17alpha-methyl-17beta-hydroxy-5-androstan-3-one);			Mesterolone
(1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);			Methandriol
(methylandrostenediol)(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);			Me
thandrostenolone
(Methandienone)(Dehydromethyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-
1,4-dien-3-one);			Methasterone
(2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);			Methenolone
(1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);			17alpha-methyl-3beta,17be
ta-dihydroxy-5a-androstane;			17alpha-methyl-3alpha,17beta-dihydroxy-5a-androsta
ne;			17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);			17alpha-methyl-4-hy
droxynandrolone
(17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);			Methyldienolone
(17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);			Methyltrienolone
(17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);			17-Methyltestosterone
(Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);			Miboler
one
(7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);			17alpha-methyl-delta1
-dihydrotestosterone
(17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-alpha-methyl-1-test
osterone);			Nandrolone
(19-Nortestosterone)(17beta-hydroxyestr-4-en-3-one);			19-nor-4,9(10)-androstadi
enedione (estra-4,9(10)-diene-3,17-dione);			19-nor-4-androstenediol
(3beta,17beta-dihydroxyestr-4-ene);			19-nor-4-androstenediol
(3alpha,17beta-dihydroxyestr-4-ene);			19-nor-5-androstenediol
(3beta,17beta-dihydroxyestr-5-ene);			19-nor-5-androstenediol
(3alpha,17beta-dihydroxyestr-5-ene);			19-nor-4-androstenedione
(estr-4-en-3,17-dione);			19-nor-5-androstenedione
(estr-5-en-3,17-dione);			Norbolethone
(13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);			Norclostebol
(4-chloro-17beta-hydroxyestr-4-en-3-one);			Norethandrolone
(17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);			Normethandrolone
(17alpha-methyl-17beta-hydroxyestr-4-en-3-one);			Oxandrolone
(17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);			Oxymesterone
(Oxymestrone)(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);			Oxymetholo
ne
(Anasterone)(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan
-3-one);			Prostanozol
(17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);			Stanolone
(4-Dihydrotestosterone)(Dihydrotestosterone)(17beta-hydroxy-androstan-3-one);			
Stanozolol
(Androstanazole)(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyr
azole);			Stenbolone
(17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);			Testolactone
(1-Dehydrotestololactone)(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
acid lactone);			Testosterone
(17beta-hydroxandrost-4-en-3-one);			Tetrahydrogestrinone
(13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);			Trenbolone
(Trienbolone)(Trienolone)(17beta-hydroxyestr-4,9,11-trien-3-one); and			Any
salt, ester, or ether of a drug or substance described or listed in this
paragraph. However, such term does not include an anabolic steroid which is
expressly intended for administration through implants to cattle or other
nonhuman species and which has been approved by the United States Secretary of
Health and Human Services for such administration. If any person prescribes,
dispenses, or distributes any such steroid for human use, such person shall be
considered to have prescribed, dispensed, or distributed an anabolic steroid
within the meaning of this subsection.

7. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
capsule in a drug product approved by the U.S. Food and Drug Administration.

HISTORY: 1972, c. 798, § 54-524.84:8; 1976, c. 614; 1977, c. 302; 1979, c. 387;
1982, c. 505; 1988, cc. 283, 765; 1992, c. 737; 2000, cc. 135, 348; 2003, c.
640; 2005, c. 119; 2006, c. 346; 2007, c. 14; 2010, c. 423; 2013, c. 233; 2014,
c. 74; 2015, c. 303.